OncoCyte Corporation (LON:0KCC)

Market Cap	44.15M
Revenue (ttm)	528.99K
Net Income (ttm)	-32.54M
Shares Out	n/a
EPS (ttm)	-3.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	308
Average Volume	2,815
Open	2.780
Previous Close	2.765
Day's Range	2.768 - 2.780
52-Week Range	0.208 - 4.226
Beta	1.01
RSI	59.04
Earnings Date	Mar 19, 2025

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design an...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2009
• Employees: 46
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0KCC

Financial Performance

In 2023, OncoCyte's revenue was $1.50 million, an increase of 56.89% compared to the previous year's $958,000. Losses were -$28.72 million, -60.88% less than in 2022.

Financial numbers in USD